Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Segment Profit and Loss Including Significant Expense

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the periods indicated:

	Three Months Ended
	March 31,
	2025		2024
External costs
Clinical research organization expenses
COVALENT - 101	$	1,001	$	458
COVALENT - 102		614		352
COVALENT - 103		739		695
COVALENT - 111		2,242		7,760
COVALENT - 112		502		1,733
Other clinical related expenses		2,487		3,903
Preclinical activities related expenses		1,956		2,965
Expenses related to manufacturing of clinical and research material		848		2,658
Other external costs		2,572		1,716
Internal costs:
Personnel-related expenses (including    stock-based compensation)		7,827		9,507
Facilities and other allocated expenses		2,109		2,029
Total research and development expenses	$	22,897	$	33,776

	Three Months Ended
	March 31,
	2025		2024
External costs	$	2,266	$	1,798
Internal costs:
Personnel-related expenses (including    stock-based compensation)		4,090		5,103
Facilities and other allocated expenses		459		382
Total general and administrative expenses	$	6,815	$	7,283

Reconciliation of segment loss from operations to net loss:

	Three Months Ended
	March 31,
	2025			2024
Loss from operations of reportable segments	$	(29,712	)	$	(41,059	)
Interest and other income, net		450			1,998
Net loss	$	(29,262	)	$	(39,061	)

Reconciliation of Segment Loss From Operations to Net Loss

Reconciliation of segment loss from operations to net loss:

	Three Months Ended
	March 31,
	2025			2024
Loss from operations of reportable segments	$	(29,712	)	$	(41,059	)
Interest and other income, net		450			1,998
Net loss	$	(29,262	)	$	(39,061	)